Related Experiment Video
Updated: Mar 11, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor
Bahman Akbari1, Safar Farajnia, Nosratollah Zarghami
1aDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences bDrug Applied Research Center cStudent Research Committee dBiotechnology Research Center eInfection and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz fCardiogenetic Research Laboratory, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abstract:
Overexpression of epidermal growth factor receptor (EGFR) plays a significant role in the development and metastasis of many solid tumors. Strategies based on anti-EGFR immunotoxins have shown promising results in several studies, but immunogenicity of antibody and toxin moieties is a limitation of this type of therapeutics. In the present study, a novel humanized anti-EGFR immunotoxin (huscFv-PE25) was developed by genetic fusing of a humanized anti-EGFR single-chain variable fragment (huscFv) with a modified Pseudomonas aeruginosa exotoxin A (PE25KDEL). The reactivity and toxicity of this immunotoxin with tumor cells were assessed by dot-blot, enzyme-linked immunosorbent assay, and MTT procedures. Results of enzyme-linked immunosorbent assay and dot-blot assay indicated that the immunotoxin recognizes and efficiently binds to EGFR-overexpressing tumor cells. MTT assay showed a specific growth-inhibitory effect of huscFv-PE25 on EGFR-overexpressing A431 cells, without any inhibitory effect on EGFR-negative cells. In conclusion, the results of this study indicated that huscFv-PE25 can recognize and exert an inhibitory effect on EGFR-overexpressing cancer cells, despite its smaller size and lower immunogenicity. This may provide a basis for the development of novel clinical therapeutic agents against EGFR-overexpressing tumor cells.
Insights
Researchers developed a novel humanized anti-epidermal growth factor receptor (EGFR) immunotoxin, huscFv-PE25. This targeted therapy effectively inhibits EGFR-overexpressing cancer cells, offering a promising new approach for cancer treatment with reduced immunogenicity.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) overexpression is crucial in solid tumor development and metastasis.
- Anti-EGFR immunotoxins show therapeutic potential but face limitations due to immunogenicity.
- A novel immunotoxin is needed to overcome existing therapeutic challenges.
Purpose of the Study:
- To develop and characterize a novel humanized anti-EGFR immunotoxin, huscFv-PE25.
- To evaluate the binding affinity and specificity of huscFv-PE25 to EGFR-overexpressing tumor cells.
- To assess the cytotoxic effects of huscFv-PE25 on EGFR-overexpressing cancer cells.
Main Methods:
- Genetic fusion of a humanized anti-EGFR single-chain variable fragment (huscFv) with a modified Pseudomonas aeruginosa exotoxin A (PE25KDEL).
- Dot-blot and enzyme-linked immunosorbent assay (ELISA) to assess immunotoxin reactivity and binding.
- MTT assay to evaluate the specific growth-inhibitory effect on EGFR-overexpressing and EGFR-negative cells.
Main Results:
- The immunotoxin huscFv-PE25 demonstrated efficient recognition and binding to EGFR-overexpressing tumor cells via ELISA and dot-blot assays.
- MTT assays confirmed a specific growth-inhibitory effect of huscFv-PE25 on EGFR-overexpressing A431 cells.
- No inhibitory effect was observed on EGFR-negative cells, indicating target specificity.
Conclusions:
- The novel humanized anti-EGFR immunotoxin, huscFv-PE25, effectively recognizes and inhibits EGFR-overexpressing cancer cells.
- huscFv-PE25 exhibits reduced immunogenicity compared to previous immunotoxins, making it a potentially safer therapeutic option.
- This study provides a foundation for developing new clinical therapeutic agents targeting EGFR-overexpressing tumors.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
